Recce Pharmaceuticals Ltd Stock OTC Markets
Stocks
RECEF
AU000000RCE5
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
17:33:35 24/06/2025 +04
|
5-day change | 1st Jan Change | ||
| 0.2200 USD | -56.00% |
|
-.--% | - |
| 08-31 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-31 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 113M 81M 69.75M 65.85M 59.89M 112M 7.73B 784M 302M 3.94B 304M 297M 12.51B | P/E 2027 * |
-4.35x | P/E 2028 * | 3.33x |
|---|---|---|---|---|---|
| Enterprise Value | 138M 98.87M 85.14M 80.38M 73.11M 137M 9.44B 957M 368M 4.81B 371M 363M 15.26B | EV / Sales 2027 * |
11.1x | EV / Sales 2028 * | 1.2x |
| Free-Float |
62.73% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | -56.00% |
| 3 years | 0.22 |  | 0.6 |
| 5 years | 0.22 | | 0.6 |
| 10 years | 0.22 | | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -56.00% | -.--% | - | - | 78.27M | |
| -0.11% | -3.20% | +49.61% | +91.49% | 1,002B | |
| -0.27% | -3.22% | +50.51% | +65.89% | 644B | |
| +1.63% | -2.57% | +21.19% | +71.12% | 443B | |
| -0.63% | -1.06% | +28.11% | +34.59% | 343B | |
| +0.43% | -14.61% | +9.88% | +27.26% | 262B | |
| +0.93% | -1.82% | -1.82% | +8.41% | 245B | |
| -2.25% | -13.63% | +36.61% | +47.43% | 212B | |
| -0.90% | -5.09% | -15.47% | -57.75% | 199B | |
| -0.58% | -3.21% | +25.10% | +90.54% | 181B | |
| Average | -5.40% | -5.00% | +22.63% | +42.11% | 392.19B | |
| Weighted average by Cap. | +0.43% | -4.24% | +31.90% | +57.11% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 12.5M 8.95M 7.7M 7.27M 6.62M 12.38M 854M 86.6M 33.33M 435M 33.59M 32.86M 1.38B | 54.3M 38.87M 33.48M 31.6M 28.75M 53.78M 3.71B 376M 145M 1.89B 146M 143M 6B |
| Net income | -25.1M -17.97M -15.47M -14.61M -13.29M -24.86M -1.72B -174M -66.94M -874M -67.48M -65.99M -2.77B | 33.4M 23.91M 20.59M 19.44M 17.68M 33.08M 2.28B 231M 89.08M 1.16B 89.79M 87.82M 3.69B |
| Net Debt | 24.96M 17.87M 15.39M 14.53M 13.22M 24.73M 1.71B 173M 66.58M 869M 67.11M 65.64M 2.76B | -48.1M -34.44M -29.65M -28M -25.46M -47.64M -3.29B -333M -128M -1.67B -129M -126M -5.32B |
Employees
-
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
- RECEF Stock
Select your edition
All financial news and data tailored to specific country editions
